EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Creatine kinase elevation in chronic hepatitis B patients with telbivudine therapy: influence of telbivudine plasma concentration and single nucleotide polymorphisms of TK2, RRM2B, and NME4

Tianye He, Bicui Chen, Yaqun Li, Yun Song, Jian Wu, Biyu Xiong, Bin Wang, Jianfei Long

European Journal of Clinical Pharmacology · 2024

DOI: 10.1007/s00228-024-03674-w ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Journal of Clinical Pharmacology, 2024. Verfasst von Tianye He und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, 200040, China. Hauptthemen laut MEDLINE: Telbivudine, Hepatitis B, Chronic, Polymorphism, Single Nucleotide, Antiviral Agents. Die Arbeit nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Sailing Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To study the correlations of genetic variants of telbivudine phosphorylase kinases and telbivudine plasma concentration with creatine kinase elevation in chronic hepatitis B patients who received telbivudine. METHODS: An observational study was performed in China chronic hepatitis B patients receiving telbivudine therapy at 600 mg once daily. Plasma concentration was measured 12 h after taking telbivudine using ultra-performance liquid chromatography-tandem mass spectrometry and SNPs located in RRM2B, TK2, and NME4 was detected by MALDI-TOF mass spectrometry. All statistical analyses were performed with R 4.3.1 and all graphs were drawn by Origin 2023b and P value < 0.05 was considered statistically significant. RESULTS: A total of 140 patients receiving telbivudine therapy were recruited with a median plasma concentration of 952.49 (781.07-1238.98) ng/mL. The value of plasma concentration was proportional to the grade of creatine kinase elevation and the best telbivudine plasma concentration threshold to discriminate the grade 3/4 CK elevation was 1336.61 ng/mL. Multivariate analysis revealed that plasma concentration and rs3826160 were the independent risk factor of telbivudine-induced creatine kinase elevation. Patients with TC and CC genotype in rs3826160 not only had a higher incidence of creatine kinase elevation but also a higher plasma concentration than TT genotype carriers. CONCLUSION: Chronic hepatitis B patients with TC and CC genotype in rs3826160 have high telbivudine plasma concentration are at risk of elevated creatine kinase.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TelbivudineHepatitis B, ChronicPolymorphism, Single NucleotideAntiviral AgentsCreatine KinaseHumansFemaleMaleAdultMiddle AgedThymidine PhosphorylaseThymidineThymidine Kinase

Stichwörter der Autor:innen

Chronic hepatitis BCreatine kinase elevationGenetic polymorphismsPlasma concentrationTelbivudine

Substanzen

TelbivudineAntiviral AgentsCreatine Kinasethymidine kinase 2Thymidine PhosphorylaseThymidineThymidine Kinase

Autor:innen und Institutionen

  • Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, 200040, China.
  • Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, 200040, China. Wangbin@huashan.org.cn.
  • Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, 200040, China. 15111030044@fudan.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Shanghai Sailing Program

Zitieren

APA

He, T., Chen, B., Li, Y., Song, Y., Wu, J., Xiong, B., Wang, B., & Long, J. (2024). Creatine kinase elevation in chronic hepatitis B patients with telbivudine therapy: influence of telbivudine plasma concentration and single nucleotide polymorphisms of TK2, RRM2B, and NME4. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-024-03674-w

Vancouver

He T, Chen B, Li Y, Song Y, Wu J, Xiong B, et al. Creatine kinase elevation in chronic hepatitis B patients with telbivudine therapy: influence of telbivudine plasma concentration and single nucleotide polymorphisms of TK2, RRM2B, and NME4. European Journal of Clinical Pharmacology. 2024. doi:10.1007/s00228-024-03674-w

BibTeX
@article{He2024,
  author = {He, Tianye and Chen, Bicui and Li, Yaqun and Song, Yun and Wu, Jian and Xiong, Biyu and Wang, Bin and Long, Jianfei},
  title = {Creatine kinase elevation in chronic hepatitis B patients with telbivudine therapy: influence of telbivudine plasma concentration and single nucleotide polymorphisms of TK2, RRM2B, and NME4},
  journal = {European Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1007/s00228-024-03674-w}
}
Kostenlos starten →